Vidya Mave, MD, MPH, is a Research Associate faculty member at the Johns Hopkins School of Medicine as well as Director and Clinical Research Site (CRS) Leader of the Byramjee Jeejeebhoy Government Medical College (BJGMC)-JHU Clinical Trials Unit (CTU), a collaborative research partnership in Pune, India that is part of the world’s largest HIV therapeutic trial networks (the AIDS Clinical Trials Group [ACTG] and the International Maternal Pediatric and Adolescent AIDS clinical Trial Network [IMPAACT]).

Dr. Mave has more than 12 years of combined experience in clinical practice, education and research in infectious diseases and has published over 20 peer-reviewed research publications. Following a short tenure as Assistant Professor of Infectious Diseases at Tulane University School of Medicine, Dr. Mave joined the Johns Hopkins CCGHE. She now coordinates all clinical research activities at the BJGMC-JHU CTU, which conducts phase I, II, and III clinical trials of therapeutic drug interventions for HIV and co-morbid infections, including TB and hepatitis, in adults (including pregnant women) and children. Her research interests include the epidemiology of latent TB infection among pregnant women, the role of Vitamin D levels in pediatric TB infection and patterns of TB drug resistance in Pune. In addition, Dr. Mave has mentored more than 16 pre- and postdoctoral trainees from Hopkins and is available to mentor trainees participating in the BJGMC-JHU HIV-TB Fogarty Research Training Program.

Dr. Mave received a MBBS in Medicine from Karnatak University, Dhjarwad, India, and a Masters in Public Health from Tulane University. She completed her Internal Medicine training at St. Barnabas Hospital in New York followed by a post-doctoral fellowship in Infectious Diseases at Tulane University and Long Island Jewish Medical Center. Dr. Mave is Board Certified in Internal Medicine and Infectious Diseases by the American Board of Internal Medicine.

• Co-Investigator in IMPAACT 2001, IMPAACT 1073, ACTG 5302, ACTG5362 (Clo-fast), PHOENIx study
• Member, End-Organ Disease and Inflammation Transformative Science Group (Feb2016-Nov2017)
• Member, Tuberculosis Transformative Science Group
• Member TBSC